RecruitingPhase 2NCT04440280

Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy

Studying Corneal dystrophy

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Massachusetts Eye and Ear Infirmary
Principal Investigator
Ula Jurkunas, MD
Mass Eye and Ear
Intervention
N-acetyl cysteine (NAC) 10% solution(drug)
Enrollment
45 enrolled
Eligibility
21 years · All sexes
Timeline
2020 – 2027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04440280 on ClinicalTrials.gov

Other trials for Corneal dystrophy

Additional recruiting or active studies for the same condition.

See all trials for Corneal dystrophy →

← Back to all trials